Literature DB >> 27534663

Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.

Wataru Kikushima1, Yoichi Sakurada2, Atsushi Sugiyama1, Naohiko Tanabe1, Atsuki Kume1, Hiroyuki Iijima1.   

Abstract

PURPOSE: To compare the efficacy of two different initial treatment modalities on visual outcome, need for retreatment, and angiographic improvement during 12-month follow-up for polypoidal choroidal vasculopathy (PCV).
METHODS: A retrospective medical chart review was performed for 66 eyes from 66 patients with treatment-naïve PCV. Visual and angiographic improvements and the incidence of retreatment for recurrence or residual pathology were compared between two groups that underwent either intravitreal aflibercept injection (IAI) monotherapy (n = 33) or combined photodynamic therapy (PDT) with IAI (n = 33).
RESULTS: Best-corrected visual acuity improved significantly (P < 0.001) in both groups at each of the 3-monthly visits during the 12-month follow-up period, with no difference between groups at 12 months (P = 0.56). The relative risk of the need for retreatment was significantly lower in the combined PDT and IAI group than in the IAI monotherapy group (P = 0.007). Angiographic regression of polypoidal vascular lesions occurred more frequently in the combined PDT group than in the IAI monotherapy group at 3 (87.5 % vs 56.7 %) and 12 months (68.8 % vs 60.0 %) (p = 0.0065 and p = 0.47 respectively).
CONCLUSIONS: The combination of PDT with IAI as the initial treatment for PCV may be superior to IAI monotherapy in terms of disease-stabilizing efficacy, but with equivalent visual gain at 12 months.

Entities:  

Keywords:  Aflibercept; Photodynamic therapy; Polypoidal choroidal vasculopathy; Retreatment-free period

Mesh:

Substances:

Year:  2016        PMID: 27534663     DOI: 10.1007/s00417-016-3467-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  17 in total

1.  EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

Authors:  Adrian Koh; Won Ki Lee; Lee-Jen Chen; Shih-Jen Chen; Yehia Hashad; Hakyoung Kim; Timothy Y Lai; Stefan Pilz; Paisan Ruamviboonsuk; Erika Tokaji; Annemarie Weisberger; Tock H Lim
Journal:  Retina       Date:  2012-09       Impact factor: 4.256

2.  Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration.

Authors:  Ziad F Bashshur; Alex R Schakal; Georges M El-Mollayess; Samer Arafat; Dalida Jaafar; Haytham I Salti
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

3.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

4.  Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up.

Authors:  Hiroaki Bessho; Shigeru Honda; Hisanori Imai; Akira Negi
Journal:  Retina       Date:  2011-09       Impact factor: 4.256

5.  ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.

Authors:  Chikako Hara; Miki Sawa; Kaori Sayanagi; Kohji Nishida
Journal:  Retina       Date:  2016-01       Impact factor: 4.256

6.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

7.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

8.  Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.

Authors:  Wai-Man Chan; Dennis S C Lam; Timothy Y Y Lai; David T L Liu; Kenneth K W Li; Yi Yao; Tak-Hung Wong
Journal:  Ophthalmology       Date:  2004-08       Impact factor: 12.079

9.  Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroko Aikawa; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2007-04-30       Impact factor: 5.258

10.  Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.

Authors:  Hae Min Kang; Hyoung Jun Koh; Christopher Seungkyu Lee; Sung Chul Lee
Journal:  Am J Ophthalmol       Date:  2013-11-22       Impact factor: 5.258

View more
  12 in total

1.  Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.

Authors:  Masahiro Morimoto; Hidetaka Matsumoto; Kensuke Mimura; Hideo Akiyama
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-01       Impact factor: 3.117

2.  Proteolytic Degradation and Inflammation Play Critical Roles in Polypoidal Choroidal Vasculopathy.

Authors:  Sandeep Kumar; Hiroyuki Nakashizuka; Alex Jones; Alyssia Lambert; Xuchen Zhao; Megan Shen; Mackenzie Parker; Shixian Wang; Zachary Berriochoa; Amrita Fnu; Stephanie VanBeuge; Patricia Chévez-Barrios; Mark Tso; Jon Rainier; Yingbin Fu
Journal:  Am J Pathol       Date:  2017-09-21       Impact factor: 4.307

Review 3.  The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review.

Authors:  Yimin Wang; Mengxi Shen; Jinwei Cheng; Xiaodong Sun; Peter K Kaiser
Journal:  J Ophthalmol       Date:  2020-08-13       Impact factor: 1.909

4.  Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis.

Authors:  Long-Hui Han; Li-Fei Yuan; Xu Liang; Xin Jia; Ming-Lian Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

5.  Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy.

Authors:  Wataru Kikushima; Yoichi Sakurada; Atsushi Sugiyama; Seigo Yoneyama; Naohiko Tanabe; Mio Matsubara; Fumihiko Mabuchi; Hiroyuki Iijima
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

6.  Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study.

Authors:  Kei Takayama; Hiroki Kaneko; Keiko Kataoka; Kyoko Hattori; Eimei Ra; Taichi Tsunekawa; Hiroshi Fukukita; Fuminori Haga; Yasuki Ito; Hiroko Terasaki
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

7.  One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Hsin-Yu Weng; Tzu-Lun Huang; Pei-Yao Chang; Jia-Kang Wang
Journal:  BMC Pharmacol Toxicol       Date:  2019-05-14       Impact factor: 2.483

8.  Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV.

Authors:  Fengjiao Li; Aihua Ma; Bojun Zhao
Journal:  Biomed Res Int       Date:  2020-04-23       Impact factor: 3.411

Review 9.  Polypoidal choroidal vasculopathy treatment options: A meta-analysis.

Authors:  Tianwei Qian; Xinxin Li; Mengya Zhao; Xun Xu
Journal:  Eur J Clin Invest       Date:  2017-12-18       Impact factor: 4.686

10.  Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.

Authors:  João Pedro Marques; Cláudia Farinha; Miguel Ângelo Costa; Ângela Ferrão; Sandrina Nunes; Rufino Silva
Journal:  BMJ Open       Date:  2017-08-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.